Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of GLPG1205 in Healthy Male Subjects
NCT02143856Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- May 2014
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of GLPG1205 in idiopathic pulmonary fibrosis (IPF) and ulcerative colitis (UC) (2 arms), sponsored by Galapagos NV. Primary endpoint: Amount of GLPG1205 in plasma up to 504 hours. Started May 2014; status: completed.
02
Drugs
GLPG1205
03
Conditions
idiopathic pulmonary fibrosis (IPF)ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02143856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02143856.